The general public's willingness to pay for tax increases to support unrestricted access to an alzheimer's disease medication

PharmacoEconomics

Volumn 30, Issue 11, 2012, Pages 1085-1095

  Oremus, Mark ^a   Tarride, Jean Eric ^a,b   Raina, Parminder ^a   Thabane, Lehana ^a,b   Foster, Gary ^a,b   Goldsmith, Charlie H ^a,b   Clayton, Natasha ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALZHEIMER DISEASE; ARTICLE; CANADA; COGNITIVE DEFECT; DISEASE COURSE; FEMALE; HEALTH SURVEY; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; TAX;

ADULT; ALZHEIMER DISEASE; CANADA; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; FINANCING, PERSONAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; QUESTIONNAIRES; TAXES;

EID: 84867287485     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11594180-000000000-00000     Document Type: Article

References (27)

1. Burns A, Iliffe S. Alzheimer's disease. BMJ 2009; 338: 467-71
2. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362: 329-44
3. Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001; 344: 1111-6
4. Alzheimer's Association. 2009 Alzheimer's disease facts and figures. Alzheimers Dement 2009; 5: 234-70
5. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119-22
6. Canadian Study of Health and Aging. Canadian Study of Health and Aging: study methods and prevalence of dementia. CMAJ 1994; 150: 899-913
7. Ostbye T, Crosse E. Net economic costs of dementia in Canada. CMAJ 1994; 151: 1457-64
8. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379-97
9. Zarit S, Orr N, Zarit J. The hidden victims of Alzheimer's disease: families under stress. New York: New York University Press, 1985
10. Oremus M, Tarride JE, Clayton N, et al. Support for a tax increase to provide unrestricted access to an Alzheimer's disease medication: a survey of the general public in Canada. BMC Health Serv Res 2009; 9: 246
11. Dieckmann L, Zarit SH, Zarit JM, et al. The Alzheimer's Disease Knowledge Test. Gerontologist 1988; 28: 402-7
12. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Pol 1990; 16: 199-208
13. Massoud F, Leger GC. Pharmacological treatment of Alzheimer disease. Can J Psychiatry 2011 Oct; 56 (10): 579-88
14. Bank of Canada. Monthly average exchange rates: 10-year lookup [online]. Available from URL: http://www.bankofcanada.ca/en/rates/exchange-avg.html [Accessed 2011 Jan 3]
15. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall, 1993
16. Oremus M, Tarride JE. A systematic review of the use of contingent valuation in Alzheimer's disease research. Dement Int J Soc Res Pract 2008; 7: 461-80
17. Chiu L, Tang K-Y, Liu Y-H, et al. Willingness of families caring for victims of dementia to pay for nursing home care: results of a pilot study in Taiwan. J Manag Med 1998; 12: 349-60
18. Konig M, Wettstein A. Caring for relatives with dementia: willingness-to-pay for a reduction in caregiver's burden. Expert Rev Pharmacoecon Outcomes Res 2002; 2: 535-47
19. Nocera S, Bonato D, Telser H. The contingency of contingent valuation: how much are people willing to pay against Alzheimer's disease? Int J Health Care Finance Econ 2002; 2: 219-40
20. Werner P, Schnaider-Beeri M, Aharon J, et al. Family caregivers' willingness to pay for drugs indicated for the treatment of Alzheimer's disease. Dementia 2002; 1: 59-74
21. Wu G, Lanctot KL, Herrmann N, et al. The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach. CNS Drugs 2003; 17: 1045-57
22. Negrin MA, Pinilla J, Leon CJ. Willingness to pay for alternative policies for patients with Alzheimer's disease. Health Econ Policy Law 2008; 3: 257-75
23. Bayoumi AM. The measurement of contingent valuation for health economics. Pharmacoeconomics 2004; 22: 691-700
24. Gustavsson A, Jonsson L, McShane R, et al. Willingness-topay for reductions in care need: estimating the value of informal care in Alzheimer's disease. Int J Geriatr Psychiatry 2010; 25: 622-32
25. Konig M, Zweifel P. Willingness-to-pay against dementia: effects of altruism in between patients and their spouse caregivers [working paper no. 0410]. Zurich: Socioeconomic Institute - University of Zurich, 2004
26. Raina PS, Wolfson C, Kirkland SA, et al. The Canadian Longitudinal Study on Aging (CLSA). Can J Aging 2009; 28: 221-9
27. Rafii MS. The pulse of drug development for Alzheimer's disease. Rev Recent Clin Trials 2010; 5: 57-62